1
|
Farissi FZ, El Annaz H, El Alaoui MA, Elkochri S, Tagajdid MR, Abi R, Amine SA, Alaoui N, Kasouati J, Touil N, Frikh R, Hjira N, El Fahime EM, Mrani S. Investigation of CCR5-Δ32 (rs333) genetic polymorphism frequency and its relationship with HIV-1 susceptibility and disease progression: A Moroccan case-control study. GENE REPORTS 2019. [DOI: 10.1016/j.genrep.2019.100391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
2
|
Zhao Q, Zhang C, Jiang Y, Wen Y, Pan P, Li Y, Zhang G, Zhang L, Qiu M. Short Communication: Investigating a Chain of HIV Transmission Events Due to Homosexual Exposure and Blood Transfusion Based on a Next Generation Sequencing Method. AIDS Res Hum Retroviruses 2015; 31:1225-9. [PMID: 26355677 DOI: 10.1089/aid.2015.0178] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
This study investigates a chain of HIV transmission events due to homosexual exposure and blood transfusion in China. The MiSeq platform, a next generation sequencing (NGS) system, was used to obtain genetic details of the HIV-1 env region (336 base pairs). Evolutionary analysis combined with epidemiologic evidence suggests a transmission chain from patient T3 to T2 through homosexual exposure and subsequently to T1 through blood transfusion. More importantly, a phylogenetic study suggested a likely genetic bottleneck for HIV in homosexual transmission from T3 to T2, while T1 inherited the majority of variants from T2. The result from the MiSeq platform is consistent with findings from the epidemiologic survey. The MiSeq platform is a powerful tool for tracing HIV transmissions and intrapersonal evolution.
Collapse
Affiliation(s)
- Qi Zhao
- 1 National AIDS Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention , Beijing, China
| | - Chen Zhang
- 2 National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention , Beijing, China
| | - Yan Jiang
- 1 National AIDS Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention , Beijing, China
| | - Yujie Wen
- 1 National AIDS Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention , Beijing, China
| | - Pinliang Pan
- 1 National AIDS Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention , Beijing, China
| | - Yang Li
- 2 National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention , Beijing, China
| | - Guiyun Zhang
- 1 National AIDS Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention , Beijing, China
| | - Lei Zhang
- 3 Research Center for Public Health, School of Medicine, Tsinghua University , Beijing, China
- 4 Melbourne Sexual Health Centre , Alfred Health, Melbourne, Victoria, Australia
- 5 Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University , Melbourne, Victoria, Australia
| | - Maofeng Qiu
- 1 National AIDS Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention , Beijing, China
| |
Collapse
|
3
|
Kagoné TS, Bisseye C, Méda N, Testa J, Pietra V, Kania D, Yonli AT, Compaoré TR, Nikiéma JB, de Souza C, Simpore J. A variant of DC-SIGN gene promoter associated with resistance to HIV-1 in serodiscordant couples in Burkina Faso. ASIAN PAC J TROP MED 2014; 7S1:S93-6. [PMID: 25312200 DOI: 10.1016/s1995-7645(14)60211-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2014] [Revised: 05/09/2014] [Accepted: 06/18/2014] [Indexed: 11/29/2022] Open
Abstract
OBJECTIVE To study the involvement of variations in 4 genes associated with susceptibility and/or protection against HIV-1 in serodiscordant couples in Burkina Faso, namely, genes encoding HLA-B57, interferon regulatory factor 1 (IRF1), dendritic cell-specific ICAM3-grabbing nonintegrin (DC-SIGN) and CCR5 delta 32 (CCR5Δ32). METHODS Two DC-SIGN and two IRF1 single nucleotide polymorphisms (SNPs) as well as HLA-B57*01 and CCR5Δ32 alleles were genotyped in 51 serodiscordant couples in Burkina Faso. DC-SIGN, IRF1 and HLA-B57*01 genotyping was carried out by real time PCR using TaqMan assays (Applied Biosystems, USA and Sacace Biotechnologies, Italy). CCR5Δ32 deletion was investigated by PCR. RESULTS The two SNPs of DC-SIGN promoter showed a significant genotypic difference in serodiscordant couples. After multivariate analysis, only the association between DC-SIGN rs2287886 and HIV-1 remained significant (P<0.01). No association was found between IRF1 SNPs and HIV-1 infection. CCR5Δ32 wild type allele was found in 100% of serodiscordant couples. A high frequency of HLA-B57*01 allele was found in the HIV-positive (78%) compared with HIV-negative group (51%), however this difference was no longer significant after the correction of the sex confounding effect in the logistic regression model. CONCLUSIONS Our study suggests a protective role of a variation of DC-SIGN promoter and genetic resistance to HIV-1 in serodiscordant couples in Burkina Faso.
Collapse
Affiliation(s)
- Thérèse Samdapawindé Kagoné
- Biomolecular Research Center Pietro Annigoni CERBA/Labiogene University of Ouagadougou, Burkina Faso; Centre MURAZ Bobo-Dioulasso, Burkina Faso
| | - Cyrille Bisseye
- Biomolecular Research Center Pietro Annigoni CERBA/Labiogene University of Ouagadougou, Burkina Faso; Laboratory of Molecular and Cellular Biology, University of Science and Technique of Masuku (USTM), Franceville, Gabon.
| | | | - Jean Testa
- Centre MURAZ Bobo-Dioulasso, Burkina Faso
| | | | | | - Albert Théophane Yonli
- Biomolecular Research Center Pietro Annigoni CERBA/Labiogene University of Ouagadougou, Burkina Faso
| | - Tegwindé Rebeca Compaoré
- Biomolecular Research Center Pietro Annigoni CERBA/Labiogene University of Ouagadougou, Burkina Faso
| | - Jean Baptiste Nikiéma
- Biomolecular Research Center Pietro Annigoni CERBA/Labiogene University of Ouagadougou, Burkina Faso
| | | | - Jacques Simpore
- Biomolecular Research Center Pietro Annigoni CERBA/Labiogene University of Ouagadougou, Burkina Faso
| |
Collapse
|
4
|
Zinc finger endonuclease targeting PSIP1 inhibits HIV-1 integration. Antimicrob Agents Chemother 2014; 58:4318-27. [PMID: 24820090 DOI: 10.1128/aac.02690-14] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Genome editing using zinc finger nucleases (ZFNs) has been successfully applied to disrupt CCR5 or CXCR4 host factors and inhibit viral entry and infection. Gene therapy using ZFNs to modify the PSIP1 gene, which encodes the lens epithelium-derived growth factor (LEDGF) protein, might restrain an early step of the viral replication cycle at the integration level. ZFNs targeting the PSIP1 gene (ZFNLEDGF) were designed to specifically recognize the sequence after the integrase binding domain (IBD) of the LEDGF/p75 protein. ZFNLEDGF successfully recognized the target region of the PSIP1 gene in TZM-bl cells by heteroduplex formation and DNA sequence analysis. Gene editing induced a frameshift of the coding region and resulted in the abolishment of LEDGF expression at the mRNA and protein levels. Functional assays revealed that infection with the HIV-1 R5 BaL or X4 NL4-3 viral strains was impaired in LEDGF/p75 knockout cells regardless of entry tropism due to a blockade in HIV-1 proviral integration into the host genome. However, residual infection was detected in the LEDGF knockout cells. Indeed, LEDGF knockout restriction was overcome at a high multiplicity of infection, suggesting alternative mechanisms for HIV-1 genome integration rather than through LEDGF/p75. However, the observed residual integration was sensitive to the integrase inhibitor raltegravir. These results demonstrate that the described ZFNLEDGF effectively targets the PSIP1 gene, which is involved in the early steps of the viral replication cycle; thus, ZFNLEDGF may become a potential antiviral agent for restricting HIV-1 integration. Moreover, LEDGF knockout cells represent a potent tool for elucidating the role of HIV integration cofactors in virus replication.
Collapse
|
5
|
Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, Eisele E, Haase A, Ho YC, Hütter G, Justement JS, Keating S, Lee TH, Li P, Murray D, Palmer S, Pilcher C, Pillai S, Price RW, Rothenberger M, Schacker T, Siliciano J, Siliciano R, Sinclair E, Strain M, Wong J, Richman D, Deeks SG. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 2013; 9:e1003347. [PMID: 23671416 PMCID: PMC3649997 DOI: 10.1371/journal.ppat.1003347] [Citation(s) in RCA: 232] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2012] [Accepted: 03/20/2013] [Indexed: 11/29/2022] Open
Abstract
There is intense interest in developing curative interventions for HIV. How such a cure will be quantified and defined is not known. We applied a series of measurements of HIV persistence to the study of an HIV-infected adult who has exhibited evidence of cure after allogeneic hematopoietic stem cell transplant from a homozygous CCR5Δ32 donor. Samples from blood, spinal fluid, lymph node, and gut were analyzed in multiple laboratories using different approaches. No HIV DNA or RNA was detected in peripheral blood mononuclear cells (PBMC), spinal fluid, lymph node, or terminal ileum, and no replication-competent virus could be cultured from PBMCs. However, HIV RNA was detected in plasma (2 laboratories) and HIV DNA was detected in the rectum (1 laboratory) at levels considerably lower than those expected in ART-suppressed patients. It was not possible to obtain sequence data from plasma or gut, while an X4 sequence from PBMC did not match the pre-transplant sequence. HIV antibody levels were readily detectable but declined over time; T cell responses were largely absent. The occasional, low-level PCR signals raise the possibility that some HIV nucleic acid might persist, although they could also be false positives. Since HIV levels in well-treated individuals are near the limits of detection of current assays, more sensitive assays need to be developed and validated. The absence of recrudescent HIV replication and waning HIV-specific immune responses five years after withdrawal of treatment provide proof of a clinical cure. There is intense interest in developing a cure for HIV. How such a cure will be quantified and defined is not known. We applied a series of measurements of HIV persistence to the study of an HIV+ adult who has exhibited evidence of cure after a stem cell transplant. Samples from blood, spinal fluid, lymph node, and gut were analyzed in multiple laboratories using different approaches. No HIV was detected in blood cells, spinal fluid, lymph node, or small intestine, and no infectious virus was recovered from blood. However, HIV was detected in plasma (2 laboratories) and HIV DNA was detected in the rectum (1 laboratory) at levels considerably lower than those expected in antiretroviral treated patients. The occasional, low-level HIV signals might be due to persistent HIV or might reflect false positives. The sensitivity of the current generation of assays to detect HIV RNA, HIV DNA, and infectious virus are close to the limits of detection. Improvements in these tests will be needed for future curative studies. The lack of rebounding virus after five years without therapy, the failure to isolate infectious virus, and the waning HIV-specific immune responses all indicate that the Berlin Patient has been effectively cured.
Collapse
Affiliation(s)
- Steven A. Yukl
- San Francisco VA Medical Center (SFVA) and University of California, San Francisco (UCSF), San Francisco, California, United States of America
| | - Eli Boritz
- Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Michael Busch
- Blood Systems Research Institute (BSRI), San Francisco, California, United States of America
| | | | - Tae-Wook Chun
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Daniel Douek
- Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Evelyn Eisele
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
| | - Ashley Haase
- University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Ya-Chi Ho
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
| | - Gero Hütter
- Institute of Transfusion Medicine and Immunology, Heidelberg University, Mannheim, Germany
| | - J. Shawn Justement
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Sheila Keating
- Blood Systems Research Institute (BSRI), San Francisco, California, United States of America
| | - Tzong-Hae Lee
- Blood Systems Research Institute (BSRI), San Francisco, California, United States of America
| | - Peilin Li
- San Francisco VA Medical Center (SFVA) and University of California, San Francisco (UCSF), San Francisco, California, United States of America
| | - Danielle Murray
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Sarah Palmer
- Department of Diagnostics and Vaccinology, Swedish Institute for Infectious Disease Control and Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Solna, Sweden
| | - Christopher Pilcher
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California, United States of America
| | - Satish Pillai
- San Francisco VA Medical Center (SFVA) and University of California, San Francisco (UCSF), San Francisco, California, United States of America
| | - Richard W. Price
- Department of Neurology, University of California, San Francisco (UCSF), San Francisco, California, United States of America
| | | | - Timothy Schacker
- University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Janet Siliciano
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
| | - Robert Siliciano
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
- Howard Hughes Medical Institute, Baltimore, Maryland, United States of America
| | - Elizabeth Sinclair
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California, United States of America
| | - Matt Strain
- University of California San Diego (UCSD), La Jolla, California, and Veterans Affairs San Diego Healthcare System, San Diego, California, United States of America
| | - Joseph Wong
- San Francisco VA Medical Center (SFVA) and University of California, San Francisco (UCSF), San Francisco, California, United States of America
| | - Douglas Richman
- University of California San Diego (UCSD), La Jolla, California, and Veterans Affairs San Diego Healthcare System, San Diego, California, United States of America
| | - Steven G. Deeks
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California, United States of America
- * E-mail:
| |
Collapse
|